Emend: adverse event reports filed with FDA

5,750

reports as suspect product

0% of all reports · about 256 a year

161

reports, 12 months to June 2026

433 in the 12 months before

77.5%

marked serious by the reporter

83.3% across the class

17.3%

record death among outcomes, as reported

992 reports · not verified by FDA

Reports by month, five years

Reports by the month FDA received them. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

By year received

2026 covers reports received through June 2026 only.

Reactions recorded in the reports

share of Emend reports recording the termmedian drug in substance p/neurokinin-1 receptor antagonist

1. Dyspnoeashortness of breath12.3%707
2. Pyrexiafever10.9%624
3. Nauseafeeling sick10.3%594
4. Hypersensitivityan allergic-type reaction9.4%542
5. Rashskin rash8.6%496
6. Vomitingbeing sick8.2%474
7. Fatiguetiredness8.2%470
8. Pruritusitching7.7%443
9. Diarrhoealoose or frequent stools7.5%434
10. Infusion related reactiona reaction during or soon after an infusion7%404
11. Hepatic enzyme increasedraised liver enzymes6.8%393
12. Confusional stateconfusion6.8%392
13. Stomatitissore mouth6.6%379
14. Systemic lupus erythematosuslupus, an autoimmune disease6.5%372
15. Gastrointestinal disorder6.5%371
16. Infectionan infection, type not specified6.4%369
17. Impaired healingslow healing6.4%367
18. Alopeciahair loss6.3%365
19. Hand deformity6.3%361
20. Glossodynia6.2%359
21. Weight increasedweight gain6.2%359
22. Duodenal ulcer perforation6.2%356
23. Off label useused for a purpose or in a way not on the label6.2%355
24. Folliculitis6.2%354
25. Abdominal discomfortstomach discomfort6%345
26. Helicobacter infection5.9%342
27. Swellingswelling5.9%342
28. Sinusitissinus infection5.9%339
29. Malaisegeneral feeling of being unwell5.9%338
30. Rheumatoid arthritisrheumatoid arthritis, an inflammatory joint disease5.9%338

Top 30 of 856 MedDRA preferred terms recorded across these reports, with a plain-language gloss where one is available. One report can record several terms. The hollow bar is the median share across the 3 drugs in the substance p/neurokinin-1 receptor antagonist class; it describes the reports, not the patients. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Outcomes recorded

Outcome flags as the reporter set them; a report can carry several, and "other serious" is FDA's own category for serious reports outside the named outcomes. Grey bar: all 8,823 reports in the class. FDA has not verified any outcome and states that the reports "cannot be used to estimate the incidence of these events."

Patients and reporters

Age and sex as stated in the report; the reporter's qualification is the primary source recorded by FDA. 32.7% of reports give the United States as the country of the event or reporter.

Reason for use recorded

The indication field is filled in by the reporter and is often blank; shares are of all 5,750 reports.

Drugs most often listed in the same reports

Other products listed in reports where Emend is a suspect product, whatever their own role. Co-listing means the two were recorded together; it says nothing about either product's part in the event. Only the 2,500 most-reported names are counted here.

In context

Shares are of reports, not of patients treated. The number of people taking a product is not in the data, so none of these figures is a rate, and differences between columns reflect who takes a product, who reports and how long it has been sold. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Other drugs in the substance p/neurokinin-1 receptor antagonist class

Ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic." A brand and its generic are separate rows because reporters name them separately.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A report counts here when it lists Emend as a suspect or interacting product; reports listing it only as a concomitant medication (6,483) are excluded. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.